GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...
Pharmaceutical Technology on MSN6d
Curevo procures $110m and former-GSK exec for shingles vaccine candidateCurevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...
In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...
Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...
Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...
Vaccination against shingles may reduce dementia risk, suggesting viral infections play a crucial role in Alzheimer’s disease ...
GlaxoSmithKline has filed its shingles vaccine in Europe, as it seeks to boost sales with a new wave of drugs. The EU filing of Shingrix follows a US filing last month for the drug, which analysts ...
Curevo is taking on biotech giant GlaxoSmithKline, which sells Shingrix, its shingles vaccine approved in 2017. Medicxi, a European biotech-focused firm, led the Series B round. Other backers ...
Former Chair of GSK’s vaccine business and Chief Scientific ... B round to advance development of amezosvatein, its vaccine for shingles. Leading the round is new investor Medicxi, a European ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback